Talarozole, a selective inhibitor of P450-mediated all-trans retinoic acid for the treatment of psoriasis and acne

Current Opinion in Investigational Drugs

Volumn 9, Issue 11, 2008, Pages 1228-1237

  Geria, A N ^a   Scheinfeld, N S ^b  

^a RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

^b Department of Dermatology ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 [2 [5,6 DIHYDRO 5,5 DIMETHYL 8 (4 METHYLPHENYL) 2 NAPHTHYL]ETHYNYL]BENZOIC ACID; ADAPALENE; CYTOCHROME P450 INHIBITOR; CYTOKERATIN; DRUG METABOLITE; INTERLEUKIN 1; KI 67 ANTIGEN; NATURAL KILLER CELL RECEPTOR; PLACEBO; R 143191; RETINOIC ACID; RETINOID; TALAROZOLE; UNCLASSIFIED DRUG;

ACNE; ANTIINFLAMMATORY ACTIVITY; BURNING SENSATION; CHEILITIS; CLINICAL TRIAL; CONTACT DERMATITIS; DEPRESSION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG EXCRETION; DRUG HALF LIFE; DRUG INDICATION; DRUG METABOLISM; DRUG SAFETY; DRUG STRUCTURE; DRUG SYNTHESIS; ECZEMA; EPISTAXIS; ERYTHEMA; GENE EXPRESSION; HAIR LOSS; HEADACHE; HUMAN; HYPERTRIGLYCERIDEMIA; IMMUNOHISTOCHEMISTRY; KERATINIZATION; MAXIMUM PLASMA CONCENTRATION; MONOTHERAPY; MOUSE; MULTIPLE DRUG DOSE; NONHUMAN; OVARIECTOMY; PATENT; PRURITUS; PSORIASIS; PSORIASIS VULGARIS; RAT; REVIEW; SINGLE DRUG DOSE; SKIN WATER LOSS; STRUCTURE ACTIVITY RELATION; VOLUNTEER; XEROSIS; XEROSTOMIA;

ACNE VULGARIS; ANIMALS; BENZOTHIAZOLES; CLINICAL TRIALS AS TOPIC; CYTOCHROME P-450 ENZYME SYSTEM; ENZYME INHIBITORS; HUMANS; PSORIASIS; STRUCTURE-ACTIVITY RELATIONSHIP; TRETINOIN; TRIAZOLES;

EID: 54949083936     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (56)

1. 131792 Retinoids in psoriasis and disorders of keratinization. Fritsch PO J AM ACAD OF DERMATOL 1992 27 6 Pt 2 8-14
2. 374896 R-115866 inhibits all-trans-retinoic acid metabolism and exerts retinoidal effects in rodents. Stoppie P, Borgers M, Borghgraef P, Dillen L, Goossens J, Sanz G, Szel H, Hove C, van Nyen G J PHARMACOL EXP THER 2000 293 1 304-312 •• A comprehensive preclinical trial assessing the selectivity, potency and retinoidal activity of talarozole in several animal cutaneous models. This was the first study to demonstrate reversibility of the effects of a retinoic acid receptor antagonist and the ability to upregulate hepatic CYP26 mRNA expression.
3. 429475 R-115866: A selective retinoic acid metabolism inhibitor acts topically as a retinoidal agent in cutaneous model systems. Gindimenico G, Stoppie P, VanWauve J, Mezick V, Liebel J, Mack W, Mallon J, Li W, Shapiro S J INVEST DERMATOL 2001 117 2 Abs 952
4. 464512 Clinical programs. Barrier Therapeutics Inc COMPANY WORLD WIDE WEB SITE 2002 September 19
5. 506403 Biopartnering - Axxima Pharmaceuticals AG. Axxima Pharmaceuticals AG ANNU BIOPARTNERING EUROPE MET 2003 11 October 12-14
6. 509149 Barrier Therapeutics Inc: Company & product information. Barrier Therapeutics Inc COMPANY WORLD WIDE WEB SITE 2003 October 16
7. 605256 Allergan receives written response from FDA on oral tazarotene. Allergan Inc PRESS RELEASE 2005 June 02
8. 613029 Rambazole, a potent inhibitor of all-trans retinoic acid metabolism, applied topically to mouse tail skin exerts retinoid mimetic activity. Stoppie P, Van Wauwe J, Wouters L, Borgers M J INVEST DERMATOL 2004 122 3 Abs 420
9. 631716 Allergan reports third quarter operating results and increases full year earnings guidance; Pharmaceutical sales increased 25 percent for the third quarter; Board of directors declares third quarter dividend. Allergan Inc PRESS RELEASE 2005 November 01
10. 748461 Isotechnika enrols first patient in European/Canadian phase III psoriasis clinical trial. Isotechnika Inc PRESS RELEASE 2006 December 05
11. 771238 Oral retinoic acid metabolism blocking agent rambazole for plaque psoriasis: An immunohistochemical study. Bovenschen HJ, Otero ME, Langewouters AMG, van Vlijmen-Willems IMJJ, van Rens DWA, Seyger MMB, van d Kerkhof PCM Br J DERMATOL 2007 156 2 263-270 • A unique study focusing on the molecular biological changes induced by talarozole as evidenced by immunohistochemistry. Valuable quantitative data regarding trends in epidermal keratinocyte markers during treatment were obtained.
12. 804690 Barrier discontinues liarozole development for ichthyosis. Barrier Therapeutics Inc PRESS RELEASE 2007 June 14
13. 804969 Oral liarozole vs acitretin in the treatment of ichthyosis: A phase II/III multicentre, double-blind, randomized, active-controlled study. Verfaille CJ, Vanhoutte FP, Blanchet-Bardon C, van Steensel MA, Steijlen PM BR J DERMATOL 2007 156 5 965-973
14. 812655 Barrier's rambazole reduces psoriasis symptoms in phase II trial. Barrier Therapeutics Inc PRESS RELEASE 2007 July 12
15. 822498 CYP26 inhibitor R-115866 increases retinoid signaling in intimal smooth muscle cells. Ocaya P, Gidlof AC, Olofsson PS, Torma H, Sirsjo A ARTERIOSCLER THROMB VASC BIOL 2007 27 7 1542-1548
16. 839945 Oral R-115866 in the treatment of moderate to severe plaque-type psoriasis. Verfaille CJ, Thissen CACB, Bovenschen HJ, Mertens J, Steijlen PM, van de Kerkhof PCM J EUR ACAD DERMAT VENEREOL 2007 21 8 1038-1046
17. 856377 Oral R-115866 in the treatment of moderate to severe facial acne vulgaris: An exploratory study. Verfaille CJ, Coel M, Boersma IH, Mertens J, Borgers M, Roseeuw D BR J DERMATOL 2007 157 1 122-126
18. 856379 Mass balance, metabolism and excretion of rambazole, a novel retinoic acid metabolism-blocking agent (RAMBA), in mice, rats and dogs. Gu ZM, Wu D, Yin F, Feng H, Barrett D DRUG METAB REV 2007 38 Suppl 2 Abs 274
19. 857034 Centocor and Janssen file for US and EU approval of ustekinumab for psoriasis. Centocor Inc PRESS RELEASE 2007 December 04
20. 862623 NCT00570986: A study comparing the safety and efficacy of two dosing regimens of ABT-874 to placebo in subjects with moderate to severe chronic plaque psoriasis. CLINICALTRIALS. GOV 2007 December 10
21. 900966 Barrier Therapeutics announces first quarter 2008 financial results. Barrier Therapeutics Inc PRESS RELEASE 2008 April 29
22. 915682 Almirall: Solutions with you in mind. Almirall Prodesfarma SA ANNUAL REPORT 2008 March 31
23. 923400 Stiefel Laboratories, Inc. commences tender offer to acquire Barrier Therapeutics, Inc. Stiefel Laboratories Inc PRESS RELEASE 2008 July 08
24. 941374 Psoriasis is common, carries a substantial burden even when not extensive and is associated with widespread treatment dissatisfaction. Stern RS, Nijsten T, Feldman SR, Margolis DJ, Rolstad T J INVEST DERMATOL SYMP PROC 2004 9 2 136-139
25. 941394 R-75251, a new inhibitor of steroid biosynthesis. Bruynseels J, De Coster R, Van Rooy P, Wouters W, Coene MC, Snoeck E, Raeymaekers A, Freyne E, Sanz G, Vanden Bussche G, Vanden Bossche H et al PROSTATE 1990 16 4 345-357
26. 941395 Exposure to retinyl esters, retinol and retinoic acids in non-pregnant women following increasing single and repeated oral doses of vitamin A. Hartmann S, Brors O, Bock J, Blomhoff R, Bausch J, Wiegand UW, Hartmann D, Hornig DH ANN NUTR METAB 2005 49 3 155-164
27. 941396 13-cis Retinoic acid is an endogenous compound in human serum. Tang G, Russell RM J LIPID RES 1990 31 2 175-182
28. 941398 Pharmacokinetics of oral isotretinoin. Wiegand U-W, Chou RC J AM ACAD DERMATOL 1998 39 2 Pt 3 S8-S12
29. 941399 Quantification of retinoic acid by gas-liquid chromatography-mass spectrometry: Total versus all-trans-retinoic acid in human plasma. Napoli JL, Pramanik BC, Williams JB, Dawson MI, Hobbs PD J LIPID RES 1985 26 3 387-392
30. 941400 A double-blind comparison of acitretin and etretinate in the treatment of severe psoriasis. Results of a Nordic multicentre study. Kragballe K, Jansen CT, Geiger JM, Bjerke JR, Falk ES, Gip L, Hjorth N, Lauharanta J, Mork NJ, Reunala T et al ACTA DERM VENEREOL 1989 69 1 35-40
31. 941408 Acitretin in psoriasis: An overview of adverse effects. Katz HI, Waalen J, Leach EE J AM ACAD DERMATOL 1999 41 3 S7-S12
32. 941416 Retinoic acid embryopathy. Lammer EJ, Chen DT, Hoar RM, Agnish ND, Benke PJ, Braun JT, Curry CJ, Fernhoff PM, Grix AW Jr, Lott IT et al N ENGL J MED 1985 313 14 837-841
33. 941436 Traditional systemic treatments have not fully met the needs of psoriasis patients: Results from a national survey. Nijsten T, Margolis DJ, Feldman SR, Rolstad T, Stern RS J AM ACAD DERMATOL 2005 52 3 Pt 1 434-444
34. 941441 Synergy between rambazole (R-115866) and retinoic acid alters the gene expression of heparin-binding EGF-like growth factor and involucrin in autocrine cultures of keratinocytes. Giltaire S, Herphelin F, Stoppie P, Poumay Y J INVEST DERMATOL 2007 127 Suppl 2s Abs 213
35. 941444 Effect of topical R-115866 (rambazole) gel on the expression of biomarkers in the skin of healthy volunteers. Cools M, Pavez-Lorie E, Borgers M, Cauwenbergh G, Vandeplassche L, Wouters L, Torma H, Vahlquist A J INVEST DERMATOL 2006 126 Supp S1 Abs 240
36. 942332 Retinoic acid receptors and cellular retinoid binding proteins: Complex interplay in retinoid signaling. Giguere V ENDOCR REV 1994 15 1 61-79
37. 942334 Retinoid therapy for psoriasis. Yamauchi PS, Rizk D, Lowe NJ DERMATOL CLIN 2004 22 4 467-476
38. 942335 Identification of the retinoic acid-inducible all-trans-retinoic acid 4-hydroxylase. White JA, Guo YD, Baetz K, Beckett-Jones B, Bonasoro J, Hsu KE, Dilworth FJ, Jones G, Petkovich M J BIOL CHEM 1996 271 47 29922-29927
39. 942338 cDNA cloning of human retinoic acid-metabolizing enzyme (hP450RAI) identifies a novel family of cytochromes P450. White JA, Beckett-Jones B, Guo YD, Dilworth FJ, Bonasoro J, Jones G, Petkovich M J BIOL CHEM 1997 272 30 18538-18541
40. 942339 Retinoic acid metabolism blocking agents (RAMBAs) for treatment of cancer and dermatological diseases. Njar VC, Gediya L, Purushottamachar P, Chopra P, Vasaitis TS, Khandelwal A, Mehta J, Huynh C, Belosay A, Patel J BIORG MED CHEM 2006 14 13 4323-4340
41. 942340 Identification of human cytochrome P450 isoforms that contribute to all-trans-retinoic acid 4-hydroxylation. McSorley LC, Daly AK BIOCHEM PHARMACOL 2000 60 4 517-526
42. 942438 Oral R-115866 in patients with moderate to severe plaque-type psoriasis: Safety evaluation from a phase IIa trial. van de Kerkhof P, Mertens J, Steijlen P J AM ACAD DERMATOL 2006 54 3 Abs AB205
43. 942444 Oral rambazole in patients with moderate to severe plaque type psoriasis - A pilot trial. Steijlen P, Thissen C, Bovenschen HJ, Mertens J, van de Kerkhof P J EUR ACAD DERMATOL VENEREOL 2005 19 Suppl 2 Abs P06.84.
44. 942497 Chapter 18: Psoriasis. Gudjonsson JE, Elder JT In: FITZPATRICK'S DERMATOLOGY IN GENERAL MEDICINE 7th edition, Wolff K, Goldsmith LA, Katz SI, Gilchrest BA, Paller AS, Leffell DJ (Eds), McGraw-Hill, New York, NY, USA 2008 191-193
45. 942499 About psoriasis. National Psoriasis Foundation WEB SITE 2008 September 10
46. 942512 Chapter 229: Retinoids. Vahlquist A, Kuenzli S, Saurat J FITZPATRICK'S DERMATOLOGY IN GENERAL MEDICINE 7th edition, Wolff K, Goldsmith LA, Katz SI, Gilchrest BA, Paller AS, Leffell DJ (Eds), McGraw-Hill, New York, NY, USA 2008 2182
47. 942514 The retinoids, a review of their clinical pharmacology. Orfanos CE, Ehlert R, Gollnick H DRUGS 1987 34 4 459-503
48. 942516 Acitretin. A review of its pharmacology and therapeutic use. Pilkington T, Brogden R DRUGS 1992 43 4 597-627
49. 942526 Tolerability, safety and pharmacokinetics of single and multiple oral dosages of R-115866 (rambazole) in healthy volunteers. Cools M, Cauwenbergh G, Vanhoutte F, Vandeplassche L CONGR EUR ACAD DERMATOL VENEREOL 2006 October 4-8 Abs P035.22
50. 942529 NCT00719121: Study on anti-inflammatory effects of topical R-115866 gel. CLINICALTRIALS.GOV 2008
51. 945092 Talarozole for moderate to severe plaque psoriasis - results of a dose-finding study. Griffiths C, van de Kerkhof P, Steijlen P, Shroot B J INVEST DERMATOL 2008 128 Suppl 1 S60
52. 946207 NCT00716144: Dose ranging study of the safety and efficacy of R-115866 in plaque psoriasis. WWW.CLINICALTRIALS.GOV 2008
53. 946527 Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. Menter A, Gottlieb A, Feldman SR, Van Voorhees AS, Leonardi CL, Gordon KB, Lebwohl M, Koo JY, Elmets CA, Korman NJ, Beutner KR et al J AM ACAD DERMATOL 2008 58 5 826-850
54. 946546 Isotretinoin, depression and suicide: A review of the evidence. Magin P, Pond D, Smith W BR J GEN PRACT 2005 55 511 134-138
55. 946571 Psoriasis is associated with lipid abnormalities at the onset of skin disease. Mallbris L, Granath F, Hamsten A, Stahle M J AM ACAD DERMATOL 2006 54 4 614-620
56. 946681 New and emerging treatments in dermatology: Acne. Katsambas A, Dessinioti C DERMATOL THER 2008 21 2 86-95